HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Commish Nominee Could Be Mixed Blessing For Cosmetics Industry

This article was originally published in The Rose Sheet

Executive Summary

Physician and former FDA official Scott Gottlieb, nominated by President Trump to head up the agency, is a more conventional pick for the role than other reportedly short-listed individuals. His science background checks a box on the cosmetics industry’s wish list, but he also – like Trump – has been a proponent of cutting red tape, while cosmetics players are actually seeking more involved federal oversight.

You may also be interested in...



Former US FDA Heads Urge Congress: Seize Opportunity For Cosmetic, Dietary Supplement Reform

Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.

Trump's Budget Blueprint: Cosmetics Opportunity Or Unhelpful Distraction?

President Trump appears to want greater user-fee contributions from FDA-regulated industries to offset cuts to federal spending in fiscal 2018. His recently released budget blueprint could complicate negotiations that cosmetics stakeholders were hoping to join, but it also could signal opportunity for an industry seeking increased regulation – and willing to pay for it.

Could Gottlieb Bring Red-Tape Scissors To FDA Sunscreen Review?

FDA Commissioner nominee Scott Gottlieb has been a vocal critic of FDA bureaucracy and excessive data demands that in his view have slowed access to life-saving drugs and medical devices in the US. His expected confirmation as FDA head could offer a new glimmer of hope to sponsors seeking GRASE status for next-generation UV filters, a process that has all but ground to a halt, according to industry advocates.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel